Mylan and Biocon announced that 48-week results from the HERITAGE study will be presented at the 2018 American Society of Clinical Oncology, or ASCO, annual meeting. The HERITAGE study compared Ogivri, the first biosimilar for Herceptin approved in the U.S., to the reference product in patients with metastatic breast cancer in combination with taxanes for the first 24 weeks and then as a monotherapy until progression. Data obtained after 48 weeks of treatment will be included as part of the Clinical Science Symposium titled, “The Arrival of Biosimilars”.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.